gefitinib Oral Tablet [Iressa]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Erlotinib (Tarceva®) and gefitinib (Iressa®) are novel oral tyrosine kinase inhibitors targeting epidermal growth factor receptor…
Lung cancer is a malignancy with the highest incidence of morbidity and mortality worldwide. The lack of effective detection…
It is well recognized that tumor hypoxia is a critical determinant for response to therapy. The effect of an EGFR inhibitor…
Upregulation of ErbB3 (HER3) signaling has been implicated as a resistance mechanism to targeted ErbB1 and ErbB2 (HER1/2…
A common problem in translational research is the fact that findings from cell line experiments cannot be transferred one to one…
A 72-year-old woman was referred to us because of the occurrence of painful toenail lesions, which had been present for 1 month…
The process of drug development is expensive and time consuming, with millions of dollars spent on the testing of new chemical…
The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing…
7097 Background: Gefitinib (Iressa®) is active as a single agent for the treatment of advanced NSCLC patients who have failed…
8522 Background: Gefitinib (ZD1839, Iressa™), an orally active inhibitor of the epidermal growth factor receptor (EGFR) tyrosine…